Results 111 to 120 of about 22,921 (208)

Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts: A Single Technology Appraisal [PDF]

, 2016
Report commissioned by the NIHR HTA ProgrammeThis report was commissioned by the NIHR HTA Programme as project number 15/64 ...
Cooper, C, Hoyle, MW, Mujica-mota, R, Rudin, C, Rule, S, Snowsill, T, Tikhonova, I, Varley-Campbell, J   +7 more
core  

The role of azacitidine in the management of myelodysplastic syndromes (MDS)

Cancer Management and Research, 2009
KS Götze, C Müller-Thomas, C PeschelDepartment of Medicine, Hematology/Oncology, Technische Universität München, Munich, GermanyAbstract: Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders ...
KS Götze, C Müller-Thomas, C Peschel   +2 more
doaj  

Case Report: Use of mirvetuximab soravtansine in a patient with platinum-resistant ovarian cancer and concomitant PARP-inhibitor-related myelodysplastic syndrome

Frontiers in Oncology
Response rates in platinum-resistant ovarian cancer remain low (16–30%) and decline with subsequent lines of therapy. Mirvetuximab soravtansine (MIRV), an antibody–drug conjugate targeting folate receptor alpha (FRα), has demonstrated clinically ...
Sophonie Shilonite Njonou Noujiep, Judith Altmann, Lars Bullinger, Lars Bullinger, Lars Bullinger, Jalid Sehouli, Jalid Sehouli, Jalid Sehouli   +7 more
doaj   +1 more source

HASH(0x563d44119a08) [PDF]

, 2009
HASH(0x563d44067a70)HASH ...
Nachtnebel, A.
core  

Azacitidine [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Efficacy of 5-hydroxytryptamine 3 receptor antagonists versus metoclopramide for preventing nausea and vomiting during azacitidine chemotherapy in patients with myelodysplastic syndromes or acute leukemia: a retrospective observational study

Journal of Pharmaceutical Health Care and Sciences
Background 5-Hydroxytryptamine 3 receptor antagonists (5-HT3RAs) and dexamethasone are recommended to prevent azacitidine-induced nausea and vomiting. In clinical practice, 5-HT3RAs or metoclopramide is often used without dexamethasone. In this study, we
Yoshinori Wakasugi, Yoshito Ikeda, Satoshi Noda, Makoto Murata, Shin-ya Morita   +4 more
doaj   +1 more source

Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma [PDF]

, 2017
Bartlett, Nancy L, et al,, Ghobadi, Armin   +2 more
core   +2 more sources

Loss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia [PDF]

, 2015
Jakšić, Ozren, Kušec, Rajko, Lasan-Trčić, Ružica, Lucijanić, Marko, Pejša, Vlatko, Štoos-Veić, Tajana   +5 more
core   +1 more source

Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials [PDF]

, 2016

core   +1 more source

A narrative review of mutant isocitrate dehydrogenase AML in Japan based on experience with ivosidenib in AGILE. [PDF]

Int J Hematol
Hiramatsu Y, Urata S, Ishikawa T, Yamauchi T.   +3 more
europepmc   +1 more source